humanized antibodies – image credits Wikipedia

 
NOVEMBER 2015 – Pradaxa patients may have a better chance of surviving emergency surgeries, due to a recent study using 5g of idarucizumab (humanized antibody fragments). In critical cases, such as patients with uncontrolled bleeding, intracranial hemmorrhage, or severe trauma following an automobile accident, there is a

NOVEMBER 2015 – Four trial dates are set for early 2017 for the consolidated multidistrict litigation (MDL) against Bayer AG and a Johnson and Johnson subsidiary regarding injuries sustained by Xarelto patients. U.S. District Judge Eldon Fallon in the Eastern District of Louisiana issued the order for trial dates of February 6, 2017 and March

 

NOVEMBER 2015 – Additional lawsuits filed this year in Ohio and Pennsylvania allege that the blood thinner drug Xarelto is causing serious injuries and death to patients nationwide. Xarelto has been proven to cause complications, such as: excessive bleeding, red or black stools, frequent nosebleeds, pink or brown urine, unexplained bruises, bruises that increase

 

OCTOBER 2015 – Although there is still no antidote for Xarelto or Eliquis, the European Medicines Agency (EMA) is fast-tracking Praxbind as an antidote for the blood thinner Pradaxa. Pradaxa patients have been injured and dying due to the anticoagulant causing uncontrollable bleeding in emergencies. The life-threatening risk of uncontrolled bleeding is a constant

 

OCTOBER 2015 – Many Xarelto lawsuits that have been filed against Johnson & Johnson and Bayer Corporation allege that the pharmaceutical companies failed to disclose the reality of the blood thinner’s risks and dangers. Xarelto has been prescribed as a blood thinner to treat many conditions, from nonvalvular atrial fibrillation, deep vein thrombosis, to

 blood thinner Xarelto causes uncontrollable bleeding and death in many Xarelto patients

OCTOBER 2015 – Jasnssen Pharmaceuticals, Inc. published a recent study on the safety of Xarelto, where the drug manufacturer attempted to minimize the injuries and uncontrolled bleeding that Xarelto patients are suffering globally. Over 45,000 patients participated in the study. Janssen and the marketing firm that assisted with the study concluded that almost 3